Secukinumab treatment of hidradenitis suppurativa: questions remain

Lancet. 2024 Feb 17;403(10427):616-617. doi: 10.1016/S0140-6736(23)01616-1.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Hidradenitis Suppurativa* / drug therapy
  • Humans
  • Severity of Illness Index

Substances

  • secukinumab
  • Antibodies, Monoclonal, Humanized